No Data
No Data
Hold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization Prospects
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Axsome Therapeutics, Inc., a biopharmaceutica
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $109 to $106.